Gay or bisexual men diagnosed with prostate cancer have particular concerns. Addressing them with your peers is far easier!
AnCan Foundation, the innovator of virtual support groups, addresses special interests in special groups. We gather peers who easily relate and can support each other.
Moderated by Gay & Bisexual peers with prostate cancer, this group addresses your specific questions. Our moderators are both technically expert and supportive.
The group is open to all levels of prostate cancer no matter where you are in your journey. AnCan offers specific prostate cancer groups at all levels. This group will focus on gay and bisexual issues less comfortable to raise in open groups rather than treatment questions.
TODAY ONLY we’ll start at 6pm ET
Next month and onward: 2nd Tuesdays of every month at 5:30pm Eastern/ 4:40pm Central/ 3:30pm Mountain/ 2:30pm Pacific always in the AnCan Schmier Room.
Meetings are free and drop-in – no sign up or pre-registration required.
Gay or bisexual men diagnosed with prostate cancer have particular concerns. Addressing them with your peers is far easier!
AnCan Foundation, the innovator of virtual support groups, addresses special interests in special groups. We gather peers who easily relate and can support each other.
Moderated by Gay & Bisexual peers with prostate cancer, this group addresses your specific questions. Our moderators are both technically expert and supportive.
The group is open to all levels of prostate cancer no matter where you are in your journey. AnCan offers specific prostate cancer groups at all levels. This group will focus on gay and bisexual issues less comfortable to raise in open groups rather than treatment questions.
2nd Tuesdays of every month at 5:30pm Eastern/ 4:40pm Central/ 3:30pm Mountain/ 2:30pm Pacific always in the AnCan Schmier Room.
Meetings are free and drop-in – no sign up or pre-registration required.
In our prostate cancer world, getting 2nd opinions is critical. It’s easy to find a medical 2nd opinion, and you can get your pathology reread by the best! But MRIs – that’s been challenging. Now there’s an affordable AI-validated option that’s proven very reliable* –ProstateID
*Sensitiviy and Specificity in the mid-90% range
Founder and Developer, Randall Jones, PhD explains the technology and its uses. Hosted by AnCan Advisory Board Member and prostate cancer peer, Dr. Mike Crosby.
No need to register ahead. Drop in and join us for this webinar.
Hi-Risk/Recurrent/Advanced PCa Video Chat, Sep 16, 2024
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!
Editor’s Pick: Germline BRCA2 Dx may impact treatment decisions (rd)
Topics Discussed
Younger high risk Gent with germline BRCA; is singlet enough for T3c (SVI); retrying daro; drug holiday endures for CHEK2 Gent; FINALLY starting HT 11 yrs after RP; HT effective; persevering w. Kwon… at least until next decision point; Testosterone discussion
For men facing cancer treatment, the risk of infertility is a major concern that is often overlooked. While fertility preservation options exist, studies consistently show that a significant proportion of patients are not adequately informed or offered these choices by their healthcare providers before undergoing potentially sterilizing cancer treatments.
The main barriers to men being aware of fertility preservation include limited knowledge and training among providers, discomfort discussing the sensitive topic, low referral rates to reproductive specialists, logistical challenges, time constraints before treatment initiation, perceptions about appropriateness based on prognosis, and patient-related factors like lack of awareness and financial concerns.
It is crucial for men to understand their options for preserving fertility, which include:
Sperm Cryopreservation (Sperm Banking)
This standard and most effective method involves collecting and freezing sperm samples before treatment for future use through assisted reproductive techniques like intrauterine insemination (IUI) or in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI). It is well-established and successful for post-pubertal males.
Testicular Tissue Cryopreservation
An experimental approach where testicular tissue is removed and frozen before cancer treatment. The frozen tissue may potentially be used later to extract sperm stem cells for reimplantation or to induce in vitro spermatogenesis. However, no live births from this method have been reported in humans yet.
Gonadal Shielding
Protecting the testicles from radiation damage by using lead shields during radiotherapy. Its effectiveness is limited by patient anatomy and radiation field requirements.
Sperm Retrieval
For males who cannot produce a semen sample, sperm can be surgically retrieved from the testicles or epididymis through techniques like testicular sperm extraction (TESE) or percutaneous epididymal sperm aspiration (PESA). Retrieved sperm can then be used for IVF/ICSI. This invasive option is appropriate when a male cannot produce a semen sample due to conditions like anejaculation, obstructive azoospermia, or prior to puberty.
While sperm cryopreservation is the most established and successful fertility preservation method, sperm retrieval combined with IVF/ICSI can be an option when cryopreserved sperm is unavailable or inadequate. However, IVF/ICSI is more invasive, costly, and has lower success rates compared to using cryopreserved sperm for insemination.
Overcoming barriers to awareness and utilization of fertility preservation options requires improved education and adherence to clinical guidelines from organizations like the American Society of Clinical Oncology (ASCO) and the American Society for Reproductive Medicine (ASRM). Establishing formal fertility preservation programs with multidisciplinary teams, patient navigators, and educational initiatives can help ensure that men with cancer have the opportunity to make informed decisions about preserving their fertility before undergoing cancer treatments.
For questions, please contact Mark Perloe at mperloe@outlook.com
